<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-167448</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Dome shaped macula associated with myopic retinochoroidosis. Use of spironolactone</dc:title>
<dc:description xml:lang="en">Cases reports: The cases are presented of three women of 22, 36 and 55 years old with bilateral myopic retinochoroidosis. They had unilateral decreased visual acuity, normal bilateral tonometry, and biomicroscopy. Funduscopy showed bilateral and unilateral myopic maculopathy, and Optical Coherence Tomography (OCT) showed a dome shaped macula with neurosensory detachment. Treatment was started with spironolactone and an improvement by OCT was shown in all cases. Discussion: The etiopathogenic mechanism of the dome shaped macula is discussed. OCT demonstrated to be the fundamental test in the follow-up of this condition. After the evidence shown, initial treatment with spironolactone is suggested (AU)</dc:description>
<dc:creator>Losada Castillo, MJ</dc:creator>
<dc:creator>Abreu Reyes, JA</dc:creator>
<dc:creator>Serrano García, MÁ</dc:creator>
<dc:creator>Rocha Cabrera, P</dc:creator>
<dc:creator>Cordovés Dorta, L</dc:creator>
<dc:creator>Ángel Pereira, D</dc:creator>
<dc:creator>Lorenzo Morales, J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Casos clínicos: Se presentan los casos de 3 mujeres de 22, 36 y 55 años de edad con retinocoroidosis miópica bilateral. Las pacientes presentan disminución de agudeza visual unilateral, tonometría y biomicroscopia bilateral normal. En la funduscopia se evidencia maculopatía unilateral, y en la tomografía de coherencia óptica (OCT), mácula en cúpula con desprendimiento neurosensorial (DNS). Iniciado tratamiento con espironolactona, en todos los casos se comprueba mejoría por OCT. Discusión: Se discute el mecanismo etiopatogénico de la mácula en cúpula. La OCT se demuestra como técnica fundamental en el seguimiento de esta patología. Tras la evidencia mostrada, se postula tratamiento inicial con espironolactona (AU)</dc:description>
<dc:source>Arch Soc Esp Oftalmol;92(10): 499-506, oct. 2017. ilus</dc:source>
<dc:identifier>ibc-167448</dc:identifier>
<dc:title xml:lang="es">Mácula en cúpula asociada a la retinocoroidosis miópica. Utilidad de la espironolactona</dc:title>
<dc:subject>^d331</dc:subject>
<dc:subject>^d28268</dc:subject>
<dc:subject>^d13531^s22073</dc:subject>
<dc:subject>^d28268^s22012</dc:subject>
<dc:subject>^d20181^s22012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d53386</dc:subject>
<dc:subject>^d55979^s22073</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d9408^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>201710</dc:date>
</metadata>
</record>
</ibecs-document>
